

Positive Data Showing Long-Term Efficacy of Deramiciel for the Treatment of Duchenne Muscular Dystrophy Released at 2025 MDA Conference

PARAMUS, NJ: March 26, 2025 – NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku), announced today that Capricor Therapeutics, Inc. (Headquarters: California, USA, CEO: Linda Marbán, NASDAQ: CAPR) has recently released positive long-term data from its ongoing HOPE-2 open label extension (“OLE”) clinical trial showing the potential of deramiciel to slow disease progression and preserve upper limb function in patients with Duchenne muscular dystrophy (“DMD”). Nippon Shinyaku and Capricor entered into an exclusive distribution agreement for deramiciel for the U.S. in January 2022. NS Pharma will be exclusively responsible for commercialization and distribution of deramiciel in the U.S.

For full details, see the Capricor press release [here](#).

About Deramiciel

Deramiciel consists of allogeneic cardiosphere-derived cells (“CDCs”), a rare population of cardiac cells that have been shown in preclinical and clinical studies to exert potent immunomodulatory and anti-fibrotic actions in preservation of cardiac and skeletal muscle function in dystrophinopathies such as DMD. CDCs act by secreting extracellular vesicles known as exosomes, which target macrophages and alter their expression profile to adopt a healing, rather than a pro-inflammatory phenotype. CDCs have been the subject of over 200 peer-reviewed scientific publications and have been administered to over 250 human subjects across several clinical trials.

About Duchenne Muscular Dystrophy (Duchenne)

Duchenne is a form of muscular dystrophy that occurs primarily in males. It causes progressive weakness and loss of skeletal, cardiac, and respiratory muscles. Early signs of Duchenne may include delayed ability to sit, stand or walk. There is a progressive loss of mobility, and by adolescence, patients with Duchenne may require the use of a wheelchair. Cardiac and respiratory muscle problems begin in the teenage years and lead to serious, life-threatening complications. For more information about Duchenne, please visit wespeakduchenne.com.

About Capricor Therapeutics, Inc.

Capricor (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. For more information, <https://www.capricor.com>.

About NS Pharma, Inc.

NS Pharma, Inc., is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. NS Pharma is a registered trademark of the Nippon Shinyaku Co., Ltd. For more information, please visit nspharma.com.

US Media Contact:

media@nspharma.com